☆ 4.7 Editorial Material

COVID-19 vaccination protects children and adolescents

LANCET INFECTIOUS DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article Medicine, General & Internal

Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance

Katherine E. Fleming-Dutra et al.

Summary: The efficacy of two doses of BNT162b2 COVID-19 vaccine against symptomatic infection was modest and decreased rapidly in children and adolescents. However, the effectiveness increased after a booster dose in adolescents.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹
Editorial Material Infectious Diseases

Effectiveness of BNT162b2 against COVID-19 in adolescents

Annabel A. Powell et al.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹
Article Medicine, General & Internal

BNT162b2 Protection against the Omicron Variant in Children and Adolescents

A. M. Price et al.

Summary: In this study evaluating BNT162b2, vaccine effectiveness against hospitalization for Covid-19 in the delta-predominant period among adolescents 12 to 18 years of age was more than 90%; during the omicron period, vaccine effectiveness was 40% against hospitalization and 79% against critical illness. Vaccine effectiveness against hospitalization was 68% among children 5 to 11 years of age.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹
Article Public, Environmental & Occupational Health

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

Ashley L. Fowlkes et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

添加到收藏夹
Article Public, Environmental & Occupational Health

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Nicola P. Klein et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

添加到收藏夹
Article Medicine, General & Internal

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022

Chiara Sacco et al.

Summary: By April 13, 2022, less than 40% of 5-11-year-olds in Italy had been vaccinated against COVID-19 with BNT162b2 (Pfizer-BioNTech), with vaccine effectiveness in preventing SARS-CoV-2 infection and severe COVID-19 found to be lower in this age group compared to individuals aged 12 years and older. The study also noted a decrease in effectiveness against infection after completion of the current primary vaccination cycle.

LANCET (2022)

添加到收藏夹
Article Medicine, General & Internal

Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17 Years

Sara Y. Tartof et al.

Summary: This study evaluated the vaccine effectiveness (VE) and durability associated with 2 doses of BNT162b2 against Delta- and Omicron-related emergency department (ED) and urgent care (UC) encounters among adolescents aged 12 to 17 years. The findings showed that 2 doses of the BNT162b2 vaccine provided high levels of protection against ED and UC encounters related to the Delta and Omicron variants in the first few months, but effectiveness waned over time, especially against Omicron. A third dose of BNT162b2 was associated with improved protection against Omicron, emphasizing the importance of boosters for adolescents in this age group.

JAMA NETWORK OPEN (2022)

添加到收藏夹
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.